PCSK9 inhibitor for coronary plaque in heart disease
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men ages 18 to 55 or women 18 to 65
- Narrowing in two or more heart arteries, with at least one blockage between 50 and 70%
- LDL cholesterol above 3.4 (if not on statins) or above 1.8 (after 4 weeks of statins)
- No prior use of PCSK9 inhibitors (like Repatha or Praluent)
- No history of hemorrhagic stroke, heart bypass, or stent placement
- No severe kidney or liver problems, and not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This trial tests whether a single dose of a cholesterol-lowering drug called a PCSK9 inhibitor can improve heart outcomes after a stent procedure. If you recently had a stent and the imaging showed significant plaque, this may help reduce future risks.
This study tests a new class of cholesterol-lowering medicine (PCSK9 inhibitor) to see if it can make unstable plaques in the carotid artery more stable, reducing the risk of stroke. If you have carotid narrowing and high LDL despite statins, this might help prevent future problems.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.